Harpoon Therapeutics (HARP) Stock Price, News & Analysis

Company Overview

Harpoon Therapeutics Inc. is a clinical-stage immunotherapy company at the forefront of revolutionizing cancer treatment and other diseases. The company is developing a novel T-cell engagers class to use the body's immune system to fight infection. 

Harpoon currently has several products in various stages of clinical trials, such as HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors and HPN217, which is in Phase I/II clinical trials for the treatment of multiple myeloma.

Shares of Harpoon have skyrocketed following the release of data from its Phase 1 clinical trial for HPN217, a single-agent candidate for pretreated patients with relapsed/refractory multiple myeloma (RRMM). The data showed clinical activity and a "tolerable safety profile," with low-grade CRS observed in 29% of patients following the first or second doses of the drug and no incidents of "Grade 3 or higher CRS." Analysts have a consensus price target of $8.75 on the stock, suggesting over 85% upside potential.

Harpoon has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products incorporating TriTAC platform technology and soluble T cell receptors. In addition, the company has a preclinical stage product, HPN601, for treating multiple solid tumor indications.

Written by Jeffrey Neal Johnson

Key Stats

• Today's Range: $23.01 to $23.01
• 50-Day Range: $22.34 to $23.01
• 52-Week Range: $3.11 to $23.21
• Volume: N/A
• Average Volume: 1.52 million shs
• Market Capitalization: $389.61 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Buy

HARP Stock Analysis - Frequently Asked Questions

How were Harpoon Therapeutics' earnings last quarter?

Harpoon Therapeutics, Inc. (NASDAQ:HARP) issued its quarterly earnings results on Monday, March, 27th. The company reported ($5.50) EPS for the quarter, missing analysts' consensus estimates of ($4.70) by $0.80. The firm earned $4.09 million during the quarter, compared to the consensus estimate of $11.06 million. Harpoon Therapeutics had a negative net margin of 81.68% and a negative trailing twelve-month return on equity of 893.55%.

When did Harpoon Therapeutics' stock split?

Harpoon Therapeutics's stock reverse split on Tuesday, September 5th 2023. The 1-10 reverse split was announced on Tuesday, September 5th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, September 5th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

When did Harpoon Therapeutics IPO?

Harpoon Therapeutics (HARP) raised $76 million in an IPO on Friday, February 8th 2019. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. Citigroup and Leerink Partners acted as the underwriters for the IPO and Canaccord Genuity and Wedbush PacGrow were co-managers.

What other stocks do shareholders of Harpoon Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Harpoon Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), CrowdStrike (CRWD), Arista Networks (ANET) and Adobe (ADBE).

Company Calendar

• Last Earnings: 3/27/2023
• Today: 2/26/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: NASDAQ:HARP
• CUSIP: N/A
• CIK: 1708493
• Web: www.harpoontx.com
• Phone: (650) 443-7400
• Fax: N/A
• Employees: 53
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($8.76)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-67,730,000.00
• Net Margins: -81.68%
• Pretax Margin: -81.67%
• Return on Equity: -893.55%
• Return on Assets: -45.98%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.89
• Quick Ratio: 1.89

Sales & Book Value

• Annual Sales: $37.34 million
• Price / Sales: 10.43
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.63 per share
• Price / Book: 14.12

Miscellaneous

• Outstanding Shares: 16,932,000
• Free Float: 14,054,000
• Market Cap: $389.61 million
• Optionable: Optionable
• Beta: 2.11